Cannabis/Hemp Isolate Extract
Formulation: CBD (99%; 0.1% THC isolate)
Herbal Extract with a high CBDLoading study record…
Loading study record…
The goal of this open-label, placebo-controlled, dosage escalation study is to learn about the safety of a Cannabis/Hemp Isolate Extract in normal healthy adults engaged in elite contact sport competition. The main question it aims to answer is: • Are cannabis/hemp-based products with high CBD safe, well-tolerated and without adverse physiological and psychological dysfunction, when administered on a daily basis? Participants will: * be given CBD and a placebo. The placebo will be taken for 2 weeks prior to starting the CBD. Participants will start on a low dose of CBD, beginning at 5 mg CBD/kg body mass, which will be increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken; * have blood samples taken to analyse how much CBD is used in the body and for how long it lasts in the body (pharmacokinetics and pharmacodynamics); * have saliva samples collected for genetic analysis; * undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-05-06
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
This research project will be a Phase I clinical trial to test the safety, efficacy and tolerability of the drug formulation. Specifically, the investigators will use a dose escalation study with all participants taking a placebo before starting the CBD regimen. This study is designed to investigate anti-inflammatory and neuroprotection of the CBD formulation to determine whether it can be used on a daily basis safely during the periods of intensive exercise (resistance) training during the off-season prior to competition. The primary research hypothesis is that cannabis/hemp-based products with high CBD are safe, well-tolerated and do not cause adverse physiological and psychological dysfunction when administered on a daily basis. Specifically, the investigators will investigate the pharmacokinetic, physiological, and psychological effects of CBD. The investigators hypothesize that the CBD formulations will be non-intoxicating (non-psychotropic), safe, well-tolerated and do not cause adverse physiological or psychological dysfunction. Secondary research hypotheses for this clinical trial: 1. Pharmacokinetic data will provide the investigators with the 'optimal' formulation for daily administration for neuroprotection from concussion 2. Plasma levels of CBD and/or its active metabolites will correlate with cerebrovascular, neurophysiology and cardiovascular physiology outcome variables. 3. Saliva levels of CBD and/or its active metabolites will correlate with plasma samples.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Formulation: CBD (99%; 0.1% THC isolate)
Herbal Extract with a high CBDEligibility
primary outcomes
Time frame: Every 15 days from Day 0 to Day 104
Monitor the participant's cerebrovascular and cardiovascular physiology before and after the dosage regimen
Time frame: Every 15 days from Day 0 to Day 104
Follow the participants enrolled in these studies at set intervals to monitor for potential harmful side effects of the high CBD cannabis/hemp extract. This will include bloodwork to assess for possible hematopoietic, renal or hepatic dysfunction, and pharmacokinetic and pharmacodynamic analysis of the dose escalation protocol
secondary outcomes
Time frame: Every 15 days from Day 0 to Day 104
Assess the inhibitory neurotransmitter δ-aminobutyric acid (GABAergic activity)
Time frame: Every 15 days from Day 0 to Day 104
Pain Behaviour Measurement system (PBM) scale
Time frame: Every 15 days from Day 0 to Day 104
Assessment of cerebral hemodynamic activity
Time frame: Every 15 days from Day 0 to Day 104
Assessment of cerebral hemodynamic activity
Time frame: up to day 104
Assess quality of life (QOL) in study participants by scores on health questionnaires and medication use
Time frame: Through study completion, From Day 0 to Day 104
Assess adverse events (AEs) in study participants by looking at sleepiness/lethargy, irritability, nausea/vomiting and diarrhea
Publications